Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/31752| Title: | Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. | Austin Authors: | Jardine, Meg J;Kotwal, Sradha S;Bassi, Abhinav;Hockham, Carinna;Jones, Mark;Wilcox, Arlen;Pollock, Carol;Burrell, Louise M ;McGree, James;Rathore, Vinay;Jenkins, Christine R;Gupta, Lalit;Ritchie, Angus;Bangi, Ashpak;D'Cruz, Sanjay;McLachlan, Andrew J;Finfer, Simon;Cummins, Michelle M;Snelling, Thomas;Jha, Vivekanand | Affiliation: | NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia. The George Institute for Global Health, University of New South Wales, Newtown, NSW, Australia. The George Institute for Global Health, UNSW, New Delhi, India. The George Institute for Global Health, Imperial College London, UK. Sydney School of Public Health, University of Sydney, Camperdown, NSW, Australia. NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia Royal North Shore Hospital, St Leonards, NSW, Australia. Medicine (University of Melbourne) Queensland University of Technology, Brisbane, QLD, Australia. All India Institute of Medical Sciences, Raipur, India. Concord Repatriation General Hospital, Concord, NSW, Australia. Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, India. Concord Repatriation General Hospital, Concord, NSW, Australia. Jivanrekha Multispecialty Hospital, Pune, India. Government Medical College and Hospital, Chandigarh, India. Sydney Pharmacy School, The University of Sydney, Camperdown, NSW, Australia. The George Institute for Global Health, University of New South Wales, Newtown, NSW, Australia. NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia. The Sydney Children's Hospitals Network, Westmead, NSW, Australia. The George Institute for Global Health, UNSW, New Delhi, India. Institute for Breathing and Sleep |
Issue Date: | 16-Nov-2022 | Date: | 2022 | Publication information: | BMJ (Clinical research ed.) 2022; 379 | Abstract: | To determine whether disrupting the renin angiotensin system with angiotensin receptor blockers will improve clinical outcomes in people with covid-19. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/31752 | DOI: | 10.1136/bmj-2022-072175 | ORCID: | 0000-0002-0160-2375 0000-0002-3294-4087 0000-0003-0750-9179 0000-0003-2126-5350 0000-0003-1736-1702 0000-0003-4128-1796 0000-0001-7167-6495 0000-0003-1863-7539 0000-0003-1863-7539 0000-0003-4315-5072 0000-0003-2717-5647 0000-0001-7291-5961 0000-0002-8164-8786 0000-0002-1142-1754 0000-0001-8831-8002 0000-0003-4674-0242 0000-0002-2785-5864 0000-0002-1371-5975 0000-0003-4670-0638 0000-0002-8015-9470 |
Journal: | BMJ (Clinical research ed.) | Start page: | e072175 | PubMed URL: | 36384746 | ISSN: | 1756-1833 | Type: | Journal Article | Subjects: | Angiotensin Receptor Antagonists/therapeutic use Telmisartan/therapeutic use |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.